

Ontario Drug Benefit Formulary/Comparative Drug Index

Edition 42

Summary of Changes – October 2017

Effective October 30, 2017

Drug Programs Policy and Strategy Branch
Ontario Public Drug Programs
Ministry of Health and Long-Term Care

[Visit Summary of Changes: Edition 42 page](#)

Table of Contents

New Multi-Source Products	2
New Off-Formulary Interchangeable (OFI) Products	5
New Nutrition Product	6
Drug Benefit Price (DBP) Changes.....	7
Discontinued Products	8
Delisted Products.....	9

New Multi-Source Products

DIN/PIN	BRAND NAME	STRENGTH	DOSAGE FORM	MFR	DBP
02462192	Mint-Clonidine	0.1mg	Tab	MIN	0.1358
02462206	Mint-Clonidine	0.2mg	Tab	MIN	0.2424

(Interchangeable with Catapres)

Therapeutic Note

Significant rebound hypertension can occur after missing even one or two doses; this drug should be avoided in patients with cardiovascular fragility or suspected problems with compliance.

DIN/PIN	BRAND NAME	STRENGTH	DOSAGE FORM	MFR	DBP
02382210	Mylan-Pregabalin	25mg	Cap	MYL	0.2058
02382229	Mylan-Pregabalin	50mg	Cap	MYL	0.3228
02382237	Mylan-Pregabalin	75mg	Cap	MYL	0.4176
02382245	Mylan-Pregabalin	150mg	Cap	MYL	0.5757
02382253	Mylan-Pregabalin	300mg	Cap	MYL	0.5757

(Interchangeable with Lyrica)

New Multi-Source Products (Continued)

DIN/PIN	BRAND NAME	STRENGTH	DOSAGE FORM	MFR	DBP
02457490	Taro-Capecitabine	150mg	Tab	TAR	0.4575
02457504	Taro-Capecitabine	500mg	Tab	TAR	1.5250

(Interchangeable with Xeloda)

Reason For Use Code and Clinical Criteria

Code 346

For the first-line treatment of patients with metastatic colorectal, small bowel and appendiceal adenocarcinomas in whom combination chemotherapy is not recommended.

NOTE: Not to be used in patients who have failed 5-flurouracil.

LU Authorization Period: Indefinite

Code 360

For the treatment of metastatic breast cancer where patients have progressed after prior chemotherapy.

LU Authorization Period: Indefinite

Code 406

For adjuvant treatment of stage 3 or high risk stage 2* colon, small bowel or appendiceal adenocarcinomas in patients who have completed surgery (within three months), who would normally be candidates for adjuvant chemotherapy with 5FU/LV.

*high risk stage 2 colon, small bowel or appendiceal adenocarcinomas is defined as one of the following:

- obstruction,
- perforation,
- poorly differentiated adenocarcinoma,
- inadequate lymph node sampling,
- T4 tumour.

LU Authorization Period: 6 Months

New Multi-Source Products (Continued)

Code 409

As part of the CAPOX (XELOX) regimen for the first-line and second-line treatment of metastatic colorectal, small bowel or appendiceal adenocarcinomas.

LU Authorization Period: Indefinite

Code 426

In combination with trastuzumab and cisplatin for the treatment of patients with HER2-positive metastatic adenocarcinoma of the stomach or gastro-esophageal junction who have not received prior anti-cancer treatment for their metastatic disease.

LU Authorization Period: Indefinite

Code 427

For the neo-adjuvant treatment of rectal cancer.

LU Authorization Period: Indefinite

Code 461

In combination with a platinum-containing product and epirubicin for the treatment of advanced (non-resectable; either locally advanced or metastatic) gastric or gastro-esophageal junction cancer.

LU Authorization Period: Indefinite

Code 474

As part of the CAPOX (XELOX) regimen for the treatment of adjuvant stage III and high risk stage II colorectal, small bowel or appendiceal adenocarcinomas.

LU Authorization Period: Indefinite

New Off-Formulary Interchangeable (OFI) Products

DIN/PIN	BRAND NAME	STRENGTH	DOSAGE FORM	MFR	UNIT PRICE
02466171	Jamp-Cetirizine	20mg	Tab	JPC	0.7535
(Interchangeable with Reactine)					

DIN/PIN	BRAND NAME	STRENGTH	DOSAGE FORM	MFR	UNIT PRICE
02461862	Apo-Erlotinib	25mg	Tab	APX	11.8667
02461870	Apo-Erlotinib	100mg	Tab	APX	47.4667
02461889	Apo-Erlotinib	150mg	Tab	APX	71.2000
(Interchangeable with Tarceva)					

DIN/PIN	BRAND NAME	STRENGTH	DOSAGE FORM	MFR	UNIT PRICE
02468050	Apo-Gefitinib	250mg	Tab	APX	62.3050
(Interchangeable with Iressa)					

New Nutrition Product

G.1 PEDIATRIC FORMULA, CHEMICALLY DEFINED – OLIGOMERIC (SEMI-ELEMENTAL)

BRAND NAME	STRENGTH, DOSAGE FORM, PACKAGE SIZE	PIN	MFR	COST (\$ PER 1000 KCAL	COST (\$) PER PKG	AMT (\$) MOHLTC PAYS	AMT (\$) PATIENT PAYS
Similac Alimentum Omega-3 & Omega-6	5.17KCAL/G, PD-400G CAN PK	09857564	ABB	7.96	16.47	16.47	0.00

Drug Benefit Price (DBP) Changes

DIN/PIN	BRAND NAME	STRENGTH	DOSAGE FORM	MFR	DBP/ UNIT PRICE
02416328**	Aubagio	14mg	Tab	GZM	56.6339
01997602	Dantrium	25mg	Cap	JHP	0.4000
02338327*	Adcirca	20 mg	Tab	LIL	12.1573
02349124	Effient	10 mg	Tab	LIL	1.9160
02046121	Novo-Clonidine	0.1mg	Tab	NOP	0.1358
02046148	Novo-Clonidine	0.2mg	Tab	NOP	0.2424
02309750	Pms-Losartan	25mg	Tab	PMS	0.3147
02309769	Pms-Losartan	50mg	Tab	PMS	0.3147
02309777	Pms-Losartan	100mg	Tab	PMS	0.3147
02302209	Pms-Risedronate	35mg	Tab	PMS	2.4893
02208237	Pms-Salbutamol	2mg/mL	Inh Sol - 2.5mL Pk	PMS	0.6750

* Off-Formulary Interchangeable (OFI) Product

** Exceptional Access Program Product

Discontinued Products

(Some products will remain on Formulary for six months to facilitate depletion of supply)

DIN/PIN	BRAND NAME	STRENGTH	DOSAGE FORM	MFR
02237886	Mylan-Acebutolol (Type S)	200mg	Tab	MYL
02229813*	Mylan-Alprazolam	1mg	Tab	MYL
02248259	Mylan-Gabapentin	100mg	Cap	MYL
02248260	Mylan-Gabapentin	300mg	Cap	MYL
02397471*	Mylan-Gabapentin	600mg	Tab	MYL
02397498*	Mylan-Gabapentin	800mg	Tab	MYL
02380749	Mylan-Montelukast	4mg	Tab	MYL
02257106	Mylan-Pravastatin	20mg	Tab	MYL
02282267	Mylan-Risperidone	1mg	Tab	MYL

* Off-Formulary Interchangeable (OFI) Product

Delisted Products

DIN/PIN	BRAND NAME	STRENGTH	DOSAGE FORM	MFR
02385058	Zarah 21	3.0mg & 0.03mg	Tab-21 Pk	COB
02385066	Zarah 28	3.0mg & 0.03mg	Tab-28 Pk	COB
02231542	Pms-Carbamazepine	100mg	Chew Tab	PMS
02231540	Pms-Carbamazepine	200mg	Chew Tab	PMS
02261863	Sandoz Carbamazepine Chewtabs	200mg	Chew Tab	SDZ

